Ep 106: A new RSV shot for kids--should your child get it? with Michael Hochman MD, MPH
Today’s episode features Dr Michael Hochman,to discuss the newly approved FDA product to prevent RSV in children, Nirsevimab (sold under the brand name Beyfortus). Recently there have been two RSV vaccines approved for adults—one for individuals over 60 years old, and one for use in pregnancy to prevent RSV in infants. On today’s podcast, the conversation will focus on Nirsevimab, a shot that has been approved by the FDA for all babies up to 8 months old and a second shot for infants up to 19 months who are considered to be at high risk of severe RSV infection. Nirsevimab is a monoclonal antibody with activity againast respiratory syncytial virus (RSV). On today's podcast we will review the benefits and potential side effects of Nirsevimab.
Dr Michael Hochman is a Harvard Medical School graduate, a Robert Wood Johnson Clinical Scholars Fellow at UCLA where he received his masters in public health, and he is the founding editor of a book series called “ 50 studies every doctor should know”, so he has a keen interest in reviewing medical studies.
Dr Jessica Hochman is a board certified pediatrician, mom to three children, and she is very passionate about the health and well being of children. Most of her educational videos are targeted towards general pediatric topics and presented in an easy to understand manner.
Do you have a future topic you'd like Dr Jessica Hochman to discuss? Email Dr Jessica Hochman askdrjessicamd@gmail.com.
Follow her on Instagram: @AskDrJessica
Subscribe to her YouTube channel! Ask Dr Jessica
Subscribe to this podcast: Ask Dr Jessica
Subscribe to her mailing list: www.askdrjessicamd.com
The information presented in Ask Dr Jessica is for general educational purposes only. She does not diagnose medical conditions or formulate treatment plans for specific individuals. If you have a concern about your child's health, be sure to call your child's health care provider.
